ID | 111176 |
著者 | |
キーワード | afatinib
gefitinib/erlotinib-induced hepatotoxicity
postoperative recurrence
non-small cell lung cancer
|
資料タイプ |
学術雑誌論文
|
抄録 | Background : Gefitinib and/or erlotinib-induced hepatotoxicity sometimes lead to treatment failure in EGFR mutation-positive patients with non-small cell lung cancer (NSCLC), even though the therapeutic effect is evident. Cases : Here, we report three postoperative NSCLC patients with recurrences who experienced severe hepatotoxicity while receiving gefitinib and/or erlotinib treatment but could be safely switched to afatinib treatment. Conclusion : Afatinib could be a well-tolerated EGFR-TKI that could be chosen for its relatively low hepatotoxicity, which is attributable to its having a different metabolic mechanism compared to other EGFR-TKIs.
|
掲載誌名 |
The Journal of Medical Investigation
|
ISSN | 13496867
13431420
|
cat書誌ID | AA11166929
AA12022913
|
出版者 | Faculty of Medicine Tokushima University
|
巻 | 63
|
号 | 1-2
|
開始ページ | 149
|
終了ページ | 151
|
並び順 | 149
|
発行日 | 2016-02
|
EDB ID | |
出版社版DOI | |
出版社版URL | |
フルテキストファイル | |
言語 |
eng
|
著者版フラグ |
出版社版
|
部局 |
医学系
|